HIV

The right balance of stem cell dose, cell type, and timing of antiretroviral therapy (ART) could potentially lead to a spontaneous cure of HIV, according to the study authors.

As patients with HIV are living longer, they are also being diagnosed with chronic conditions that have become increasingly common in recent decades, putting them at higher risk of COVID-19 hospitalization and death.

At the virtual 2020 ASHP Midyear Clinical Meeting and Exhibition, Elyse Tung, PharmD, BCACP, discussed key counseling points for pharmacists to address with patients when prescribing and managing PrEP.

The FDA has approved Rukobia (fostemsavir) for the treatement of human immunodeficiency virus 1 (HIV-1) infection.

Additional non-oral options could provide more manageable forms of PrEP treatment for patients, potentially increasing global uptake of PrEP in the future.

Further, the study showed cabotegravir was 89% more effective than daily oral FTC/TDF for pre-exposure prophylaxis (PrEP).

Further, the study showed cabotegravir was 89% more effective than daily oral FTC/TDF for pre-exposure prophylaxis (PrEP).

The US Department of Health & Human Services released guidance at the beginning of the pandemic clarifying guidelines regarding best practices in HIV care.

This activity is supported by an educational grant from Janssen Therapeutics, division of Janssen Products, LP.

Conduct proper review and evaluation of ARV and DOAC pharmacokinetics and metabolism prior to recommending treatment.

Although HIV self-tests are available for retail purchase by consumers, the CDC encourages health departments to consider self-testing as an additional strategy to reach individuals most affected by the virus.

This activity is supported by an educational grant from Janssen Therapeutics, division of Janssen Products, LP.

Insurance companies are currently investigating the option of modifying which medications they will cover for HIV pre-exposure prophylaxis (PrEP) therapy, with broad implications for patient access.

Learn how retail or specialty pharmacy distribution can affect access to these important drugs.

Following the global impact of COVID-19 on the health care system in 2020, there have been some clear changes in HIV care in the United States.

Successfully implementing HIV and hepatitis C testing at drug detoxification centers could help identify and link patients to care, but would require that the test results are available to nearby health care facilities.

Although antiretroviral therapy is an important option for patients with HIV, the viral reservoir has been a major obstacle for researchers looking to effectively cure the disease.

According to results from a recent study, a functional cure for HIV may lie in identifying the viral reservoirs in which HIV places copies of its viral genetic material into cell genomes.

According to the study authors, with a higher antigen valency, antibodies have more sites to latch onto; however, including a higher antigen valency in a vaccine does not mean it will work better.

Antiretroviral therapy’s limitations lead to new efforts to treat the virus by neutralizing antibodies.

Despite, antiretroviral therapy, HIV can hide in blood and tissue.

Fingolimod (Gilenya), which is approved by the FDA to treat multiple sclerosis flare-ups, may also block HIV and reduce the latent reservoir.

A new study found that it’s safe for patients with HIV to receive HIV-positive kidneys.

As patients return to their routines of returning to pharmacies and the inevitable discussions about COVID-19 begin, it may be a good time to discuss the range of tests that the CDC recommends.

Globally, dolutegravir is expected to be a part of treatment for approximately 15 million people living with HIV by 2021.

Significant morbidity and mortality are associated with an aging population due to cardiovascular disease, which is very common in HIV-infected persons.

Fostemsavir is indicated for adults with drug resistant HIV.

Dolutegravir tablets are intended to treat pediatric patients at least 4 weeks old and at least 6 pounds who have never been treated for HIV or who have been treated, but not with an integrase strand transferase inhibitor class drug, according to the press release.

New research on the structure of HIV has revealed a promising novel drug target for treating HIV infection.

Today, we’re celebrating the clinical pharmacy specialist team at the William J. Holloway Community Program in Delaware.